0.6387
전일 마감가:
$0.689
열려 있는:
$0.6562
하루 거래량:
3.74M
Relative Volume:
0.93
시가총액:
$186.51M
수익:
-
순이익/손실:
$-63.08M
주가수익비율:
-2.3656
EPS:
-0.27
순현금흐름:
$-72.53M
1주 성능:
-11.77%
1개월 성능:
+5.55%
6개월 성능:
-32.59%
1년 성능:
-57.56%
오큐젠 Stock (OCGN) Company Profile
명칭
Ocugen Inc
전화
484-328-4701
주소
11 GREAT VALLEY PARKWAY, MALVERN, PA
OCGN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
OCGN
Ocugen Inc
|
0.6387 | 186.51M | 0 | -63.08M | -72.53M | -0.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
오큐젠 Stock (OCGN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-10-15 | 개시 | Maxim Group | Buy |
2023-03-01 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
2022-08-23 | 개시 | Mizuho | Buy |
2022-06-15 | 재개 | ROTH Capital | Buy |
2022-06-02 | 개시 | Cantor Fitzgerald | Overweight |
2021-07-26 | 개시 | Noble Capital Markets | Outperform |
2021-06-11 | 다운그레이드 | ROTH Capital | Buy → Neutral |
2021-05-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
2021-02-09 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
2021-02-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
모두보기
오큐젠 주식(OCGN)의 최신 뉴스
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Advances OCU200 Clinical Trial Amid Promising Safety Results - MSN
Stock Quote & Chart - Ocugen
Ocugen receives DSMB approval to continue dosing in Phase I trial of OCU200 - Yahoo
Ocugen’s OCU200 advances to next trial phase with safety approval By Investing.com - Investing.com Australia
ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important August 17 Deadline in Securities Class Action – OCGN - Business Wire
OCGN stock touches 52-week low at $0.52 amid market challenges By Investing.com - Investing.com South Africa
OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com India
Ocugen Advances OCU200 Trial After Safety Board Review -March 18, 2025 at 08:31 am EDT - Marketscreener.com
Ocugen says DSMB approves dosing Cohort 2 in OCU200 clinical trial - TipRanks
Ocugen’s OCU200 advances to next trial phase with safety approval - Investing.com India
Ocugen Announces Approval to Continue Dosing in Phase 1 Trial of OCU200 Following Favorable Safety Review - Nasdaq
Data and Safety Monitoring Board Reviews Cohort 1 Safety Data and Approves Dosing Cohort 2 in the Clinical Trial of OCU200—a Novel Fusion Protein for Diabetic Macular Edema - Ocugen
Data and Safety Monitoring Board Reviews Cohort 1 Safety - GlobeNewswire
Ocugen seeks its One Shining Moment - The Healthcare Technology Report.
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial - MSN
Ocugen Inc. Navigates Uncertainty Amid Potential Shifts in U.S. Fiscal and Tax Policies - MSN
SBI Securities Co. Ltd. Makes New $40,000 Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen, Inc. (NASDAQ:OCGN) Shares Acquired by Rhumbline Advisers - Defense World
Equities Analysts Offer Predictions for Ocugen Q1 Earnings - Defense World
FY2029 Earnings Estimate for Ocugen Issued By HC Wainwright - Defense World
Ocugen’s (OCGN) “Buy” Rating Reiterated at HC Wainwright - Defense World
Ocugen Secures ATMP Classification for Gene Therapies Targeting Vision Loss - MSN
Ocugen Stock Lifts Retail Investor Confidence As Q4 Revenue Crushes Estimates - MSN
Ocugen’s Strategic Advancements and Financial Stability Justify Buy Rating - TipRanks
Ocugen Reports 2024 Financial Results and Advances Gene Therapy Programs - MSN
Attention Long-Term Shareholders of Driven Brands Holdings, - GlobeNewswire
Attention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); MGP Ingredients, Inc. (NASDAQ: MGPI); and Ocugen, Inc. (NASDAQ: OCGN): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating -March 06, 2025 at 08:15 am EST - Marketscreener.com
Ocugen, Inc. (NASDAQ:OCGN) Q4 2024 Earnings Call Transcript - Insider Monkey
Ocugen’s Strategic BLA Submissions and Financial Position Support Buy Rating - TipRanks
Beyond The Numbers: 5 Analysts Discuss Ocugen Stock - Benzinga
Y Intercept Hong Kong Ltd Makes New Investment in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen: Q4 Earnings Snapshot - Midland Daily News
Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance
Ocugen Reports Progress in Gene Therapy Trials - TipRanks
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire
Ocugen Inc Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks
Around the Helix: Cell and Gene Therapy Company Updates – March 5, 2025 - CGTLive™
Ocugen Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ocugen (OCGN) Q4 2024 Earnings Call Transcript - Yahoo
Ocugen’s Geographic Atrophy and Stargardt Gene Therapies Garner Positive ATMP Opinions from EMA - CGTLive™
Earnings call transcript: Ocugen Q4 2024 beats earnings forecast By Investing.com - Investing.com UK
Ocugen to Announce Q4 and Full-Year 2024 Results with Live Webcast on March 5, 2025 - MSN
Ocugen, Inc. SEC 10-K Report - TradingView
오큐젠 (OCGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):